<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04718961</url>
  </required_header>
  <id_info>
    <org_study_id>VLX-401</org_study_id>
    <secondary_id>2020-003448-96</secondary_id>
    <nct_id>NCT04718961</nct_id>
  </id_info>
  <brief_title>A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA)</brief_title>
  <acronym>OHANA</acronym>
  <official_title>A Phase 2a/2b Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in Adult Women With Intrahepatic Cholestasis of Pregnancy and Elevated Serum Bile Acid Concentrations (OHANA).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mirum Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mirum Pharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical research study is to evaluate the efficacy, safety and&#xD;
      tolerability of the study medicine, volixibat, in patients with Intrahepatic cholestasis of&#xD;
      pregnancy (ICP) and elevated serum bile acid concentrations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 4, 2021</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in serum bile acids</measure>
    <time_frame>Through to end of treatment, up to 21 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in the weekly average worst daily itch score as measured by the Adult Itch Reported Outcome (ItchRO)</measure>
    <time_frame>Through to end of treatment, up to 21 weeks</time_frame>
    <description>The Adult ItchRO is an 11-point NRS measurement of itch severity ranging from 0=no itch to 10=worst possible itch.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants experiencing one or more of adverse perinatal outcomes</measure>
    <time_frame>Through to end of treatment, up to 21 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of adverse events</measure>
    <time_frame>Through to study completion, up to 25 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">290</enrollment>
  <condition>Intrahepatic Cholestasis of Pregnancy</condition>
  <arm_group>
    <arm_group_label>Volixibat 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to this arm will receive volixibat 20mg twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Volixibat 80mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to this arm will receive volixibat 80mg twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in this arm will receive capsules matched to the study drug minus the active volixibat substance, twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Volixibat</intervention_name>
    <description>Oral capsules, administered twice daily. Volixibat is an apical sodium-dependent bile acid transporter (ASBT) inhibitor.</description>
    <arm_group_label>Volixibat 20mg</arm_group_label>
    <arm_group_label>Volixibat 80mg</arm_group_label>
    <other_name>SHP626</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsules matched to study drug minus active substance.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female aged ≥18 and ≤45 years with a viable pregnancy.&#xD;
&#xD;
          2. Provide signed informed consent as described in the protocol and willing to comply&#xD;
             with all study visits and requirements.&#xD;
&#xD;
          3. Diagnosis of ICP.&#xD;
&#xD;
          4. Qualified level of pruritus associated with ICP, during screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. At the time of either the screening or baseline visit, decision has already been made&#xD;
             to deliver within the next 7 days, for any indication.&#xD;
&#xD;
          2. Known non-reassuring fetal status based upon antepartum testing (e.g., NST/CTG or BPP)&#xD;
             at or within 7 days before the baseline visit.&#xD;
&#xD;
          3. Known fetal anomaly likely to result in intrauterine fetal demise or neonatal death&#xD;
             within the first 30 days of life.&#xD;
&#xD;
          4. Participating in another ongoing clinical study at screening or planning to&#xD;
             participate in another contemporaneous clinical study while participating in this&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Trials Mirum</last_name>
    <phone>+16506674085</phone>
    <email>clinicaltrials@mirumpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Medinfo Mirum</last_name>
    <email>medinfo@mirumpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacy Harris</last_name>
      <phone>205-996-6262</phone>
      <email>stacylharris@uabmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Parley</last_name>
      <phone>203-500-3995</phone>
      <email>lauren.perley@yale.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Texas Medical Branch - Galveston</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liz Welch</last_name>
      <phone>409-747-6622</phone>
      <email>elwelch@UTMB.EDU</email>
    </contact>
    <contact_backup>
      <last_name>Ashley Salazar</last_name>
      <phone>409-772-0312</phone>
      <email>assalaza@utmb.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sunbola Ashimi</last_name>
      <phone>713-500-6410</phone>
      <email>sunbola.s.ashimi@uth.tmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Capital &amp; Coast District Health Board</name>
      <address>
        <city>Newtown</city>
        <state>Wellington</state>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Christchurch Women's Hospital</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medway NHS Foundation Trust</name>
      <address>
        <city>Gillingham</city>
        <state>Kent</state>
        <zip>ME7 5NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Richards Hospital</name>
      <address>
        <city>Chichester</city>
        <zip>PO19 6SE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marian Flynn-Batham</last_name>
      <email>marian.flynn-batham@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Thomas' Hospital</name>
      <address>
        <city>London</city>
        <zip>SE 1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sunderland Royal Hospital, South Tyneside Sunderland NHS Trust</name>
      <address>
        <city>Sunderland</city>
        <zip>SR4 7TP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith Ormonde</last_name>
      <phone>07903971148</phone>
      <email>judith.ormonde@nhs.net</email>
    </contact>
  </location>
  <location_countries>
    <country>New Zealand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 19, 2021</study_first_submitted>
  <study_first_submitted_qc>January 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pruritus</keyword>
  <keyword>Itch</keyword>
  <keyword>Itching</keyword>
  <keyword>Cholestasis</keyword>
  <keyword>Bile Acid</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>Pregnant</keyword>
  <keyword>Intrahepatic</keyword>
  <keyword>Liver</keyword>
  <keyword>ICP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholestasis</mesh_term>
    <mesh_term>Cholestasis, Intrahepatic</mesh_term>
    <mesh_term>Pregnancy Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Volixibat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

